Is “next-gen” CAR-T the beginning of the end of cancer?
Cancer is a word we all dread to hear yet a cure for the deadly disease has always felt so...
Cancer is a word we all dread to hear yet a cure for the deadly disease has always felt so...
Solid tumours are notoriously difficult to treat. A recently discovered cancer protein could be the reason why. The protein, known...
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a shining light...
Australian listed biotechnology company Prescient Therapeutics (ASX: PTX) today updated the market on progress on one of its personalised cancer...
Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology (ASCO) annual...
Last month, the best and brightest minds in oncology gathered (virtually) for the American Society of Clinical Oncology (ASCO) annual...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has announced that two of its assets will be used for a...
Independent Investment Research (IIR) recently authored a special investment report on pre-clinical oncology company Prescient Therapeutics (ASX: PTX) which gives...
Three hundred years ago, Adam Smith emphasised the importance of competition arguing that the “invisible hand”- the natural driving forces...
It is impossible to overstate the unprecedented disruptions the world is facing with COVID-19. Stock markets have plunged worldwide and...